Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | HEXA | P06865 | 1/20 | 0.55 |
| ▸ | HEXB | P07686 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | RGS12 | O14924 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TERT | O14746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213254 | 0.87 | FGFR1 (0.64) | FGFR1KDRPDGFRAHEXAHEXB | |
| SCHEMBL3756441 | 0.85 | FGFR1 (0.70) | FGFR1KDRPDGFRAHEXAHEXB | |
| SCHEMBL19820268 | 0.84 | FGFR1 (0.64) | FGFR1KDRPDGFRAHEXAHEXB | |
| SCHEMBL3433937 | 0.84 | POLB (0.64) | FGFR1KDRPDGFRAPOLBMEN1 | |
| SCHEMBL30926161 | 0.83 | HEXA (0.60) | FGFR1KDRPDGFRAHEXAHEXB | |
| SCHEMBL3752200 | 0.82 | FGFR1 (0.61) | FGFR1KDRPDGFRAHEXAHEXB | |
| SCHEMBL3759225 | 0.81 | FGFR1 (0.78) | FGFR1KDRPDGFRAHEXAHEXB | |
| SCHEMBL16213632 | 0.80 | ALDH1A1 (0.60) | FGFR1KDRPDGFRAHEXAHEXB | |
| SCHEMBL12463506 | 0.78 | POLB (0.66) | FGFR1KDRPDGFRAHEXAHEXB | |
| SCHEMBL14864327 | 0.77 | HEXA (0.67) | FGFR1KDRPDGFRAHEXAHEXB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878984-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878984-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878984-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2016-03-10 | — | — | US | disclosed |
| US-20140378503-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY | 2014-12-25 | — | — | US | disclosed |
| US-20140378503-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY | 2014-12-25 | — | — | US | disclosed |
| US-20140378503-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY | 2014-12-25 | — | — | US | disclosed |
| US-8829025-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829025-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130225634-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225634-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225634-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-8420665-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420665-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420665-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100303719-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100303719-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100303719-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2009089537-A2 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378503-A1 | ANTI-CANCER COMPOUNDS | TP53, MKI67, MYC | FGFR1 523/4885KDR 4148/4885PDGFRA 2798/4885 |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | MYC, NME2, TP53 | FGFR1 17/4885KDR 3380/4885PDGFRA 2765/4885 |
| US-20100303719-A1 | ANTI-CANCER COMPOUNDS | TP53, MKI67, MYC | FGFR1 523/4885KDR 4148/4885PDGFRA 2798/4885 |
| US-20130225634-A1 | ANTI-CANCER COMPOUNDS | TP53, MKI67, MYC | FGFR1 523/4885KDR 4148/4885PDGFRA 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.